The review included seven clinical trials and six observational studies, which involved more than 500,000 participants combined. Each trial and study also involved the use of three major commercial vaccines.
Researchers found efficacy for a two-dose regimen was 58 percent for adults and only 30 percent for children under age of 5. Additionally, a one-dose vaccine regimen seemed to provide similar protection as a two-dose regimen, within the six months following vaccination.
More articles on quality:
5 Maine hospitals with top nurse-patient communication scores
FDA tells NYC fertility physician to stop marketing 3-parent babies
Swedish Health CEO Dr. Guy Hudson overhauls concurrent surgery policy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
